Compugen Dirección
Dirección controles de criterios 3/4
El CEO de Compugen es Anat Cohen-Dayag , nombrado en Jun 2009, tiene una permanencia de 15.42 años. compensación anual total es $1.46M, compuesta por 32.7% salario y 67.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.063% de las acciones de la empresa, por valor de $79.13K. La antigüedad media del equipo directivo y de la junta directiva es de 5 años y 7.4 años, respectivamente.
Información clave
Anat Cohen-Dayag
Chief Executive Officer (CEO)
US$1.5m
Compensación total
| Porcentaje del salario del CEO | 32.7% |
| Permanencia del CEO | 15.4yrs |
| Participación del CEO | 0.06% |
| Permanencia media de la dirección | 5yrs |
| Promedio de permanencia en la Junta Directiva | 7.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
Aug 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
May 22Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
May 01Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Feb 17Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Oct 10Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Jun 22Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 04Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Sep 21Compugen appoints Alberto Sessa as CFO
Sep 12Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Aug 24Compugen Q2 2022 Earnings Preview
Aug 03Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Jun 23Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Mar 02Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 04Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
Aug 27Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth
Jun 28Compugen gains on takeover speculation after iTeos Therapeutics deal
Jun 14Compugen reports updated COM701 data from Phase 1 study at ASCO21
Jun 08Compugen's COM902 demonstrates potential benefit in cancer
Apr 27Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 15Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?
Feb 08
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)
Jan 04Compugen earns $2M milestone under antibody development deal with AstraZeneca
Dec 23Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 30Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Compugen: Speculative Play For Immuno-Oncology Exposure
Nov 07Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$1m | US$479k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$1m | US$479k | -US$34m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$1m | US$498k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$1m | US$453k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$941k | US$395k | -US$27m |
| Sep 30 2019 | n/a | n/a | -US$30m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$854k | US$391k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$29m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$740k | US$392k | -US$37m |
Compensación vs. Mercado: La compensación total de Anat($USD1.46M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.07K).
Compensación vs. Ingresos: La compensación de Anat ha sido consistente con los resultados de la empresa en el último año.
CEO
Anat Cohen-Dayag (57 yo)
15.4yrs
Permanencia
US$1,464,448
Compensación
Dr. Anat Cohen-Dayag, Ph D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She serves as Director at has been Chief Executive Officer and President at Compug...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 15.4yrs | US$1.46m | 0.063% $ 79.1k | |
| Chief Scientific Officer | 4.7yrs | US$540.64k | sin datos | |
| Senior Vice President of Technology Innovation | 6.8yrs | US$532.26k | sin datos | |
| Vice President of Preclinical Development | 3.6yrs | US$570.40k | sin datos | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| Head of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
| General Counsel & Corporate Secretary | 5.8yrs | sin datos | sin datos | |
| Vice President of Human Resources | 17.8yrs | sin datos | sin datos | |
| Senior VP & Senior Advisor of Data and Informatics Solutions | 5yrs | sin datos | sin datos | |
| Vice President Research and Discovery | no data | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos |
5.0yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CGEN es experimentado (5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 10.8yrs | US$1.46m | 0.063% $ 79.1k | |
| Member of Scientific Advisory Board | 4.2yrs | sin datos | sin datos | |
| Independent Director | 6.4yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 11.3yrs | sin datos | sin datos | |
| Independent Director | 6.4yrs | sin datos | sin datos | |
| Independent Chairman of the Board | 7.1yrs | sin datos | sin datos | |
| Independent Director | 6.4yrs | sin datos | sin datos | |
| Chairman of Scientific Advisory Board | 10.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 11.3yrs | sin datos | sin datos | |
| Independent Director | 5.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 11.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7.7yrs | sin datos | sin datos |
7.4yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de CGEN se considera experimentada (7.4 años de antigüedad promedio).